Indiamart
Mumbai, Maharashtra
Products & Services

Our Milestones

1969
Establishment of Themis Chemicals (now Themis Medicare) in joint partnership with GEDEON Richter Ltd. , Hungary

1971
Themis Chemicals became the Second Company in the world and First Company in India to produce Vitamin B12 by non-sterile fermentation.

1976
Themis Chemicals is the Second Company in the world and FIRST Company in India to produce Ethambutol Dihydrochloride.

1985
Themis Chemicals produces RIFAMPICIN for the FIRST TIME in India

1990
Themis Chemicals develops and produces a unique haemostat – HEMOLOK

1991
Themis Chemicals - produces SISOMICIN and is the ONLY Company other than Schering Plough of USA to master the technology

1991 / 1992
Themis Chemicals develops and introduces ANABLOKTM (Centbucridine Hydrochloride) – an anaesthetic – along with CDRI, Lucknow – FIRST OF ITS KIND IN THE WORLD.

1993
Themis Chemicals produces GENTAMICIN in India – the only Private Sector Company to do so

1995
Themis Chemicals produces FUMAGILLIN – a unique veterinary product - for the FIRST TIME in the world – exclusive manufacture for French Company

THEMIS CHEMICALS goes Public – listed on the Bombay Stock Exchange

1996
Themis Chemicals produces LOVASTATIN indigenously – FIRST TIME IN INDIA and Third Company in the world to do so

1997
Themis Chemicals bags Ministry of Science and Technology’s Department of Scientific and Industrial Research (DSIR) AWARD for LOVASTATIN

1998
Indigenously develops Simvastatin for the first time in Asia

1999
Launch of E MALTM – Alpha Beta Arteether – a THEMIS-CDRI product by the Prime Minister – Shri Atal Behari Vajpayee – Prime Minister of India on Technology Day

Themis Chemicals bags Ministry of Science and Technology’s Department of Scientific and Industrial Research (DSIR) AWARD for development of E MALTM – ALPHA BETA ARTEETHER

2001
Themis Chemicals RENAMED – THEMIS MEDICARE LIMITED

2002
Themis Medicare develops and introduces SEPGARDTM – a unique wound healing agent – FIRST TIME IN INDIA.

2003
Themis Medicare develops and introduces – CLEOFOLTM – (Lipid free Clear Propofol Injection) – FIRST TIME IN THE WORLD

Themis Medicare develops and introduces – ROFEJETTM – (Rofecoxib Injection) – the FIRST COX-2 INJECTION in the WORLD

2004
MERGER of Artemis Biotech with Themis Medicare

Themis Medicare establishes SECOND JOINT VENTURE with Gedeon Richter Ltd., Hungary under name – RICHTER THEMIS MEDICARE (INDIA) PVT. LTD. a 100% export oriented unit

2004
Themis Medicare builds new state-of-the-art facility at Hyderabad for Simvastatin Production.

2006
Themis Medicare commences operations of its state-of-the-art formulation manufacturing facility at Haridwar.

Themis Medicare develops and introduces NIMESULIDE INJECTION.

THEMISEALTM the unique ‘stops bleeding gel’ enters the European market.

Themis Joint Venture Richter Themis Medicare (India) Pvt. Ltd. commences production

Commenced cultivation of Artemisia annua & extraction of Artemisinin.

Team / Manpower

Mr. Shantilal D. Patel (1926) - Chairman - Emeritus

He is the Founder and Chairman (Non-Executive) of the Company.  He holds a Bachelor of Pharmacy degree.  Fondly addressed as Dadaji, Shri S. D. Patel stepped into the world of pharmaceuticals in the year 1952.  His hard work and tenacity set the pace and formation of Themis Medicare in 1969 (then known as Themis Chemicals).


Mr. Erik Bogsch (1947) – Director
He is a Director on the Board from Gedeon Richter Ltd.  In Gedeon Richter, he holds the key position of Managing Director since November 1992.  Mr. Bogsch is a Chemical Engineer and qualified Economic Engineer, who has been with Richter since 1970 in a number of research and development management positions.

Dr. Laszlo Kovacs (1944) – Director
He is a Director on the Board from Gedeon Richter Ltd.  In Gedeon Richter he held the position of Deputy Managing Director with the responsibility for Commerce and Marketing from 1990 to 2005.  Dr. Kovacs is currently Strategic Adviser to the Executive Board of Gedeon Richter.  He is an Economist with a University doctorate in Economic Sciences.

Mr. Lajos Kovacs (1960) – Director
He is a Director on the Board from Gedeon Richter Ltd.  He has been appointed a Director in Gedeon Richter since 2005.  Mr. Kovacs is responsible for Technical Services.  A Chemical Engineer, with postgraduate degree in pharmaceutical research, he has been with Richter since 1984 in different positions.

Mr. Hoshang N. Sinor (1944) – Chairman
He is an Independent Director on the Board since 2003.  He is also the Chairman of the Company’s Audit Committee.  Banking and Finance, at very senior management levels, are the areas of his expertise.  Mr. Sinor had held the post of Deputy Managing Director in ICICI Bank Ltd.  Presently he is the CEO of the Indian Bankers Association as well as Director on the Board of many renowned companies. 

Mr. Humayun Dhanrajgir (1936) – Independent Director
He is an Independent Director on the Board since 2004.  He is also a member of the Company’s Audit Committee.  Mr. Dhanrajgir is considered an Expert in the Pharmaceutical Industry with over 40 years of experience.  He has served Glaxo India Ltd., as Managing Director and Executive Vice Chairman.  Presently he is on the Board of many renowned companies.

Mr. Vijay Agarwal (1957) – Independent Director
He is an Independent Director on the Board since 2002.  He is also a member of the Company’s Audit Committee.  Mr. Agarwal is a practicing Chartered Accountant with expertise in finance and taxation.

Mrs. Jayshree Dinesh Patel (1951) – Whole Time Director
She is Whole Time Director on the Board.  She is actively involved in the Distribution, Administration and Financial aspects of the Company since 1984.

Dr. Sachin Dinesh Patel (1975) – Director – Business Development
He is Director-Business Development on the Board since 2004 and son of the Managing Director & CEO.  Dr. Sachin Patel is a Bachelor of Science graduate from the University of Sunderland, UK.  He also holds a Doctorate in Life Sciences & Nanotechnology from Christ’s College, University of Cambridge, UK.

Dr. Dinesh Shantilal Patel (1948) – Managing Director & CEO
He is the Managing Director & CEO on the Board and son of the Chairman.         Dr. Dinesh Patel holds a Doctorate in Medicinal Chemistry.  He is also a Fellow of the Royal Society of Chemistry,

Achievements

1969
Establishment of Themis Chemicals (now Themis Medicare) in joint partnership with GEDEON Richter Ltd. , Hungary

1971
Themis Chemicals became the Second Company in the world and First Company in India to produce Vitamin B12 by non-sterile fermentation.

1976
Themis Chemicals is the Second Company in the world and FIRST Company in India to produce Ethambutol Dihydrochloride.


1985
Themis Chemicals produces RIFAMPICIN for the FIRST TIME in India

1990
Themis Chemicals develops and produces a unique haemostat – HEMOLOK

1991
Themis Chemicals - produces SISOMICIN and is the ONLY Company other than Schering Plough of USA to master the technology

1991 / 1992
Themis Chemicals develops and introduces ANABLOKTM (Centbucridine Hydrochloride) – an anaesthetic – along with CDRI, Lucknow – FIRST OF ITS KIND IN THE WORLD.

1993
Themis Chemicals produces GENTAMICIN in India – the only Private Sector Company to do so

1995
Themis Chemicals produces FUMAGILLIN – a unique veterinary product - for the FIRST TIME in the world – exclusive manufacture for French Company

THEMIS CHEMICALS goes Public – listed on the Bombay Stock Exchange

1996
Themis Chemicals produces LOVASTATIN indigenously – FIRST TIME IN INDIA and Third Company in the world to do so

1997
Themis Chemicals bags Ministry of Science and Technology’s Department of Scientific and Industrial Research (DSIR) AWARD for LOVASTATIN

1998
Indigenously develops Simvastatin for the first time in Asia

1999
Launch of E MALTM – Alpha Beta Arteether – a THEMIS-CDRI product by the Prime Minister – Shri Atal Behari Vajpayee – Prime Minister of India on Technology Day

Themis Chemicals bags Ministry of Science and Technology’s Department of Scientific and Industrial Research (DSIR) AWARD for development of E MALTM – ALPHA BETA ARTEETHER

2001
Themis Chemicals RENAMED – THEMIS MEDICARE LIMITED

2002
Themis Medicare develops and introduces SEPGARDTM – a unique wound healing agent – FIRST TIME IN INDIA.


2003
Themis Medicare develops and introduces – CLEOFOLTM – (Lipid free Clear Propofol Injection) – FIRST TIME IN THE WORLD

Themis Medicare develops and introduces – ROFEJETTM – (Rofecoxib Injection) – the FIRST COX-2 INJECTION in the WORLD

2004
MERGER of Artemis Biotech with Themis Medicare

Themis Medicare establishes SECOND JOINT VENTURE with Gedeon Richter Ltd., Hungary under name – RICHTER THEMIS MEDICARE (INDIA) PVT. LTD. a 100% export oriented unit

2004
Themis Medicare builds new state-of-the-art facility at Hyderabad for Simvastatin Production

2006
Themis Medicare commences operations of its state-of-the-art formulation manufacturing facility at Haridwar.

Themis Medicare develops and introduces NIMESULIDE INJECTION.

THEMISEALTM the unique ‘stops bleeding gel’ enters the European

Testing Facilities

The R & D facilities is geared up to face the challenges of the post 2005 era. The major aim of the R & D centre is to : 



  • Strive to develop new chemical entities

  • Developing new and efficient processes for production of API and intermediates.

  • Further advancement in developing fermentation technology

  • Developing New Drug Delivery Systems.

Manufacturing Facility

Manufacturing Facility

ARTEMIS BIOTECH--HYDERABAD, INDIA
Products : Lovastatin, Simvastatin, Pravastatin
and other speciality API's.

THEMIS MEDICARE LTD. -- HARIDWAR, INDIA

Infrastructure

The 500 strong field force of Themis Medicare, backed by a nation wide network of over 2000 stockists, ensures that the company''s products are readily available across the nation. This combined with the quality of the products means that Themis Medicare is able to strengthen the hands of doctors by offering superior treatment and healthcare solutions. It is our constant endeavour to improve the quality of life by enabling people to do more, feel better and live longer.

Message From CEO

Dear Friends,

I am very pleased to welcome you to Themis Medicare, one of India’s leading research-based healthcare companies.

At Themis Medicare, we are dedicated to innovating healthcare. All our efforts are directed towards developing novel solutions for major unmet medical needs. Over the years, our search for better ways of maintaining and restoring health has resulted in a steady stream of pioneered therapeutic products.

We deliver a unique contribution to better healthcare. Our mission is to reduce suffering and improve health and quality of life of people all around the world. We have pursued this mission with patience, dedication, imagination and skill, for over 3 decades. Our vision is to develop targeted medicines that offer patients and physicians better, safer, more cost-effective healthcare.

The combined strengths of our API’s and Finished Pharmaceuticals businesses, coupled with our expertise in the emerging and fast growing field of biotechnology equip us to develop integrated healthcare solutions and therapeutic approaches tailored to individual patients' needs.

Our people are our strength who continuously contribute to our mission.

We also take pride in mentioning herewith that we enjoy long-term, close and good understanding with all our business partners.

Once again, welcome to Themis Medicare, a Company that is dedicated to translating a great vision into reality.

DR. DINESH PATEL, Ph.D.

R & D


The R & D facilities is geared up to face the challenges of the post 2005 era. The major aim of the R & D centre is to : 

  • Strive to develop new chemical entities
  • Developing new and efficient processes for production of API and intermediates.
  • Further advancement in developing fermentation technology
  • Developing New Drug Delivery Systems.

To,Themis Medicare Limited
RELATED COMPANIES

Indiamart

Terms of Use - Privacy Policy - Link to Us

Copyright © 1996-2014 IndiaMART InterMESH Ltd. All rights reserved.